<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:58:14 -0700</creation_date>
  <update_date>2013-01-15 18:58:14 -0700</update_date>
  <accession>HMDBP01632</accession>
  <secondary_accessions>
    <accession>6955</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Beta-1 adrenoceptor</synonym>
    <synonym>Beta-1 adrenoreceptor</synonym>
  </synonyms>
  <gene_name>ADRB1</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01924</accession>
      <name>Atenolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01932</accession>
      <name>Metoprolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00068</accession>
      <name>Epinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01849</accession>
      <name>Propranolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05020</accession>
      <name>Risperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14333</accession>
      <name>Esmolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14341</accession>
      <name>Betaxolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14366</accession>
      <name>Isoetharine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14517</accession>
      <name>Timolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14632</accession>
      <name>Sotalol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14662</accession>
      <name>Carteolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14736</accession>
      <name>Labetalol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14750</accession>
      <name>Bisoprolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14979</accession>
      <name>Dobutamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15004</accession>
      <name>Alprenolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15095</accession>
      <name>Pindolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15197</accession>
      <name>Isoproterenol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15234</accession>
      <name>Arbutamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13946</accession>
      <name>8-Hydroxycarvedilol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15324</accession>
      <name>Acebutolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15334</accession>
      <name>Nadolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15341</accession>
      <name>Levobunolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15345</accession>
      <name>Metipranolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15405</accession>
      <name>Fenoterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15407</accession>
      <name>Pirbuterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15409</accession>
      <name>Bevantolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15411</accession>
      <name>Practolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15447</accession>
      <name>Penbutolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15477</accession>
      <name>Clenbuterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15520</accession>
      <name>Oxprenolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15594</accession>
      <name>Nebivolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15627</accession>
      <name>Droxidopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15696</accession>
      <name>Bopindolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15697</accession>
      <name>Bupranolol</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled amine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>beta-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>beta1-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>10q24-q26</locus>
    <gene_sequence>&gt;1434 bp
ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG
TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTACGCGAGCAG
AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>477</residue_number>
    <molecular_weight>51322.1</molecular_weight>
    <theoretical_pi>9.03</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>56-84</region>
      <region>94-120</region>
      <region>133-154</region>
      <region>173-196</region>
      <region>223-248</region>
      <region>320-349</region>
      <region>355-377</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Beta-1 adrenergic receptor
MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG
MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV
WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC
TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM
AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP
LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV
FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP
PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>178200</genbank_protein_id>
  <uniprot_id>P08588</uniprot_id>
  <uniprot_name>ADRB1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>J03019</genbank_gene_id>
  <genecard_id>ADRB1</genecard_id>
  <geneatlas_id>ADRB1</geneatlas_id>
  <hgnc_id>HGNC:285</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK: Cloning of the cDNA for the human beta 1-adrenergic receptor.  Proc Natl Acad Sci U S A. 1987 Nov;84(22):7920-4.</reference_text>
      <pubmed_id>2825170</pubmed_id>
    </reference>
    <reference>
      <reference_text>Moore JD, Mason DA, Green SA, Hsu J, Liggett SB: Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A&amp;gt;G and c1165G&amp;gt;C. Hum Mutat. 1999 Sep 19;14(3):271.</reference_text>
      <pubmed_id>10477438</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10.  Nature. 2004 May 27;429(6990):375-81.</reference_text>
      <pubmed_id>15164054</pubmed_id>
    </reference>
    <reference>
      <reference_text>He J, Bellini M, Xu J, Castleberry AM, Hall RA: Interaction with cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) inhibits beta1-adrenergic receptor surface expression. J Biol Chem. 2004 Nov 26;279(48):50190-6. Epub 2004 Sep 9.</reference_text>
      <pubmed_id>15358775</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mason DA, Moore JD, Green SA, Liggett SB: A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999 Apr 30;274(18):12670-4.</reference_text>
      <pubmed_id>10212248</pubmed_id>
    </reference>
    <reference>
      <reference_text>Borjesson M, Magnusson Y, Hjalmarson A, Andersson B: A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J. 2000 Nov;21(22):1853-8.</reference_text>
      <pubmed_id>11052857</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ranade K, Jorgenson E, Sheu WH, Pei D, Hsiung CA, Chiang FT, Chen YD, Pratt R, Olshen RA, Curb D, Cox DR, Botstein D, Risch N: A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet. 2002 Apr;70(4):935-42. Epub 2002 Feb 18.</reference_text>
      <pubmed_id>11854867</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Mersmann HJ: Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci. 1998 Jan;76(1):160-72.</reference_text>
        <pubmed_id>9464897</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>El-Armouche A, Eschenhagen T: Beta-adrenergic stimulation and myocardial function in the failing heart.  Heart Fail Rev. 2009 Dec;14(4):225-41.</reference_text>
        <pubmed_id>19110970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Gilsbach R, Hein L: Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. Handb Exp Pharmacol. 2008;(184):261-88.</reference_text>
        <pubmed_id>18064417</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esmolol</name>
        <accession>HMDB14333</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esmolol</name>
        <accession>HMDB14333</accession>
      </metabolite>
      <reference>
        <reference_text>Jahn P, Eckrich B, Schneidrowski B, Volz-Zang C, Schulte B, Mutschler E, Palm D: Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Arzneimittelforschung. 1995 May;45(5):536-41.</reference_text>
        <pubmed_id>7612051</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esmolol</name>
        <accession>HMDB14333</accession>
      </metabolite>
      <reference>
        <reference_text>Volz-Zang C, Eckrich B, Jahn P, Schneidrowski B, Schulte B, Palm D: Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol. 1994;46(5):399-404.</reference_text>
        <pubmed_id>7957532</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esmolol</name>
        <accession>HMDB14333</accession>
      </metabolite>
      <reference>
        <reference_text>Kirshenbaum JM: Nonthrombolytic intervention in acute myocardial infarction.  Am J Cardiol. 1989 Jul 18;64(4):25B-28B.</reference_text>
        <pubmed_id>2568748</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esmolol</name>
        <accession>HMDB14333</accession>
      </metabolite>
      <reference>
        <reference_text>Jacobs JR, Maier GW, Rankin JS, Reves JG: Esmolol and left ventricular function in the awake dog.  Anesthesiology. 1988 Mar;68(3):373-8.</reference_text>
        <pubmed_id>2894187</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esmolol</name>
        <accession>HMDB14333</accession>
      </metabolite>
      <reference>
        <reference_text>Howie MB, Black HA, Zvara D, McSweeney TD, Martin DJ, Coffman JA: Esmolol reduces autonomic hypersensitivity and length of seizures induced by electroconvulsive therapy. Anesth Analg. 1990 Oct;71(4):384-8.</reference_text>
        <pubmed_id>1975995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betaxolol</name>
        <accession>HMDB14341</accession>
      </metabolite>
      <reference>
        <reference_text>McLean AJ, Zeng FY, Behan D, Chalmers D, Milligan G: Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor. Mol Pharmacol. 2002 Sep;62(3):747-55.</reference_text>
        <pubmed_id>12181453</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betaxolol</name>
        <accession>HMDB14341</accession>
      </metabolite>
      <reference>
        <reference_text>Rudoy CA, Van Bockstaele EJ: Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1119-29. Epub 2007       Apr 19.</reference_text>
        <pubmed_id>17513029</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betaxolol</name>
        <accession>HMDB14341</accession>
      </metabolite>
      <reference>
        <reference_text>Satoh N, Suzuki J, Bessho H, Kitada Y, Narimatsu A, Tobe A: Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: comparison with atenolol and propranolol. Jpn J Pharmacol. 1990 Oct;54(2):113-9.</reference_text>
        <pubmed_id>2077180</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betaxolol</name>
        <accession>HMDB14341</accession>
      </metabolite>
      <reference>
        <reference_text>Lesar TS: Comparison of ophthalmic beta-blocking agents.  Clin Pharm. 1987 Jun;6(6):451-63.</reference_text>
        <pubmed_id>2891463</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betaxolol</name>
        <accession>HMDB14341</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoetharine</name>
        <accession>HMDB14366</accession>
      </metabolite>
      <reference>
        <reference_text>Rodrigues LL, Oliveira MC, Pelegrini-da-Silva A, de Arruda Veiga MC, Parada CA, Tambeli CH: Peripheral sympathetic component of the temporomandibular joint inflammatory pain in rats. J Pain. 2006 Dec;7(12):929-36.</reference_text>
        <pubmed_id>17157779</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoetharine</name>
        <accession>HMDB14366</accession>
      </metabolite>
      <reference>
        <reference_text>Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16.</reference_text>
        <pubmed_id>17628611</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoetharine</name>
        <accession>HMDB14366</accession>
      </metabolite>
      <reference>
        <reference_text>Terra SG, McGorray SP, Wu R, McNamara DM, Cavallari LH, Walker JR, Wallace MR, Johnson BD, Bairey Merz CN, Sopko G, Pepine CJ, Johnson JA: Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int J Obes (Lond). 2005 Jul;29(7):746-54.</reference_text>
        <pubmed_id>15917856</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoetharine</name>
        <accession>HMDB14366</accession>
      </metabolite>
      <reference>
        <reference_text>Burniston JG, Tan LB, Goldspink DF: Relative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats. Exp Physiol. 2006 Nov;91(6):1041-9. Epub 2006 Sep 14.</reference_text>
        <pubmed_id>16973691</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoetharine</name>
        <accession>HMDB14366</accession>
      </metabolite>
      <reference>
        <reference_text>Muszkat M: Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Clin Pharmacol Ther. 2007 Aug;82(2):215-8. Epub 2007 Feb 28.</reference_text>
        <pubmed_id>17329986</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Nieminen T, Uusitalo H, Maenpaa J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimaki T, Kahonen M: Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol. 2005 Dec;61(11):811-9. Epub 2005 Nov 17.</reference_text>
        <pubmed_id>16315032</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium.  Br J Pharmacol. 1999 Jun;127(4):895-902.</reference_text>
        <pubmed_id>10433496</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Hirooka K, Kelly ME, Baldridge WH, Barnes S: Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res. 2000 May;70(5):611-21.</reference_text>
        <pubmed_id>10870519</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Bhattacharyya BJ, Lee E, Krupin D, Hockberger P, Krupin T: (-)-Isoproterenol modulation of maxi-K(+) channel in nonpigmented ciliary epithelial cells through a G-protein gated pathway. Curr Eye Res. 2002 Mar;24(3):173-81.</reference_text>
        <pubmed_id>12221524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Wang T, Kaumann AJ, Brown MJ: (--)-Timolol is a more potent antagonist of the positive inotropic effects of (--)-adrenaline than of those of (--)-noradrenaline in human atrium. Br J Clin Pharmacol. 1996 Aug;42(2):217-23.</reference_text>
        <pubmed_id>8864321</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sotalol</name>
        <accession>HMDB14632</accession>
      </metabolite>
      <reference>
        <reference_text>Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61.</reference_text>
        <pubmed_id>11815381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sotalol</name>
        <accession>HMDB14632</accession>
      </metabolite>
      <reference>
        <reference_text>Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2.</reference_text>
        <pubmed_id>15060759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sotalol</name>
        <accession>HMDB14632</accession>
      </metabolite>
      <reference>
        <reference_text>Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.</reference_text>
        <pubmed_id>19259968</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sotalol</name>
        <accession>HMDB14632</accession>
      </metabolite>
      <reference>
        <reference_text>Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14.</reference_text>
        <pubmed_id>8095397</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sotalol</name>
        <accession>HMDB14632</accession>
      </metabolite>
      <reference>
        <reference_text>Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202.</reference_text>
        <pubmed_id>2865685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sotalol</name>
        <accession>HMDB14632</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carteolol</name>
        <accession>HMDB14662</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carteolol</name>
        <accession>HMDB14662</accession>
      </metabolite>
      <reference>
        <reference_text>Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23.</reference_text>
        <pubmed_id>15526107</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carteolol</name>
        <accession>HMDB14662</accession>
      </metabolite>
      <reference>
        <reference_text>Chidlow G, Melena J, Osborne NN: Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol. 2000 Jun;130(4):759-66.</reference_text>
        <pubmed_id>10864881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carteolol</name>
        <accession>HMDB14662</accession>
      </metabolite>
      <reference>
        <reference_text>Floreani M, Froldi G, Quintieri L, Varani K, Borea PA, Dorigo MT, Dorigo P: In vitro evidence that carteolol is a nonconventional partial agonist of guinea pig cardiac beta1-adrenoceptors: a comparison with xamoterol. J Pharmacol Exp Ther. 2005 Dec;315(3):1386-95. Epub 2005 Sep 13.</reference_text>
        <pubmed_id>16160085</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Riva E, Mennini T, Latini R: The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br J Pharmacol. 1991 Dec;104(4):823-8.</reference_text>
        <pubmed_id>1687367</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Monopoli A, Bamonte F, Forlani A, Ongini E, Parravicini L: Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment. Arch Int Pharmacodyn Ther. 1984 Dec;272(2):256-63.</reference_text>
        <pubmed_id>6151824</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9.</reference_text>
        <pubmed_id>6355664</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Nakagawa Y, Takeda K, Sakurai H, Mitomi A, Imai S: [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Apr;77(4):435-45.</reference_text>
        <pubmed_id>7286847</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques.  J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. Epub       2009 Oct 17.</reference_text>
        <pubmed_id>19879818</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Rosendorff C: Beta-blocking agents with vasodilator activity.  J Hypertens Suppl. 1993 Jun;11(4):S37-40.</reference_text>
        <pubmed_id>8104240</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17.</reference_text>
        <pubmed_id>7684671</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Breed JG, Ciampricotti R, Tromp GP, Valster FA, Lageweg E, Van Bortel LM: Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol. 1992;20(5):750-5.</reference_text>
        <pubmed_id>1280737</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34.</reference_text>
        <pubmed_id>14757145</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4.</reference_text>
        <pubmed_id>16325050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Lipworth BJ, Irvine NA, McDevitt DG: A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135-9.</reference_text>
        <pubmed_id>1676675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Mauz AB, Pelzer H: Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol. J Cardiovasc Pharmacol. 1990 Mar;15(3):421-7.</reference_text>
        <pubmed_id>1691366</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dobutamine</name>
        <accession>HMDB14979</accession>
      </metabolite>
      <reference>
        <reference_text>Junker V, Becker A, Huhne R, Zembatov M, Ravati A, Culmsee C, Krieglstein J: Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection. Eur J Pharmacol. 2002 Jun 20;446(1-3):25-36.</reference_text>
        <pubmed_id>12098582</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dobutamine</name>
        <accession>HMDB14979</accession>
      </metabolite>
      <reference>
        <reference_text>La Rosee K, Huntgeburth M, Rosenkranz S, Bohm M, Schnabel P: The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics. 2004 Nov;14(11):711-6.</reference_text>
        <pubmed_id>15564877</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dobutamine</name>
        <accession>HMDB14979</accession>
      </metabolite>
      <reference>
        <reference_text>Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4.</reference_text>
        <pubmed_id>16325050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dobutamine</name>
        <accession>HMDB14979</accession>
      </metabolite>
      <reference>
        <reference_text>Raddatz A, Kubulus D, Winning J, Bauer I, Pradarutti S, Wolf B, Kreuer S, Rensing H: Dobutamine improves liver function after hemorrhagic shock through induction of heme oxygenase-1. Am J Respir Crit Care Med. 2006 Jul 15;174(2):198-207. Epub 2006 Apr 20.</reference_text>
        <pubmed_id>16627864</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dobutamine</name>
        <accession>HMDB14979</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alprenolol</name>
        <accession>HMDB15004</accession>
      </metabolite>
      <reference>
        <reference_text>Surman AJ, Doggrell SA: Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria. J Cardiovasc Pharmacol. 1993 Jan;21(1):35-9.</reference_text>
        <pubmed_id>7678677</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alprenolol</name>
        <accession>HMDB15004</accession>
      </metabolite>
      <reference>
        <reference_text>De Ponti F, Cosentino M, Costa A, Girani M, Gibelli G, D'Angelo L, Frigo G, Crema A: Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta 3-adrenoceptors. Br J Pharmacol. 1995 Apr;114(7):1447-53.</reference_text>
        <pubmed_id>7606348</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alprenolol</name>
        <accession>HMDB15004</accession>
      </metabolite>
      <reference>
        <reference_text>Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium.  Br J Pharmacol. 1999 Jun;127(4):895-902.</reference_text>
        <pubmed_id>10433496</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alprenolol</name>
        <accession>HMDB15004</accession>
      </metabolite>
      <reference>
        <reference_text>Brahmadevara N, Shaw AM, MacDonald A: Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol. 2003 Jan;138(1):99-106.</reference_text>
        <pubmed_id>12522078</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alprenolol</name>
        <accession>HMDB15004</accession>
      </metabolite>
      <reference>
        <reference_text>Im MJ, Holzhofer A, Bottinger H, Pfeuffer T, Helmreich EJ: Interactions of pure beta gamma-subunits of G-proteins with purified beta 1-adrenoceptor. FEBS Lett. 1988 Jan 25;227(2):225-9.</reference_text>
        <pubmed_id>2828119</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alprenolol</name>
        <accession>HMDB15004</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ: Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):496-503. Epub 2003 Nov 8.</reference_text>
        <pubmed_id>14608456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77.</reference_text>
        <pubmed_id>1687398</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Berendsen HH, Broekkamp CL, Van Delft AM: Antagonism of 8-OH-DPAT-induced behaviour in rats.  Eur J Pharmacol. 1990 Oct 2;187(1):97-103.</reference_text>
        <pubmed_id>2148726</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Watkins DJ, Lawrence AJ, Lewis SJ, Jarrott B: Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996 Aug 27;60(1-2):12-6.</reference_text>
        <pubmed_id>8884690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pindolol</name>
        <accession>HMDB15095</accession>
      </metabolite>
      <reference>
        <reference_text>Brodde OE, Michel MC, Wang XL, Zerkowski HR: Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J Hypertens Suppl. 1988 Dec;6(4):S497-500.</reference_text>
        <pubmed_id>2907348</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoproterenol</name>
        <accession>HMDB15197</accession>
      </metabolite>
      <reference>
        <reference_text>Sato M, Gong H, Terracciano CM, Ranu H, Harding SE: Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger. J Mol Cell Cardiol. 2004 Jan;36(1):43-8.</reference_text>
        <pubmed_id>14734046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoproterenol</name>
        <accession>HMDB15197</accession>
      </metabolite>
      <reference>
        <reference_text>Jurgens CW, Rau KE, Knudson CA, King JD, Carr PA, Porter JE, Doze VA: Beta1 adrenergic receptor-mediated enhancement of hippocampal CA3 network activity. J Pharmacol Exp Ther. 2005 Aug;314(2):552-60. Epub 2005 May 20.</reference_text>
        <pubmed_id>15908512</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoproterenol</name>
        <accession>HMDB15197</accession>
      </metabolite>
      <reference>
        <reference_text>Kobayashi H, Narita Y, Nishida M, Kurose H: Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK. Cell Signal. 2005 Oct;17(10):1248-53. Epub 2005 Feb 12.</reference_text>
        <pubmed_id>16038799</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoproterenol</name>
        <accession>HMDB15197</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoproterenol</name>
        <accession>HMDB15197</accession>
      </metabolite>
      <reference>
        <reference_text>Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor.  Am Heart J. 1976 Nov;92(5):661-4.</reference_text>
        <pubmed_id>10722</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arbutamine</name>
        <accession>HMDB15234</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arbutamine</name>
        <accession>HMDB15234</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arbutamine</name>
        <accession>HMDB15234</accession>
      </metabolite>
      <reference>
        <reference_text>Abou-Mohamed G, Nagarajan R, Ibrahim TM, Caldwell RW: Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47.</reference_text>
        <pubmed_id>8723169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5(1):25-38.</reference_text>
        <pubmed_id>1712335</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 1989;39(5):327-36.</reference_text>
        <pubmed_id>2575762</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality. 1989;1(4):265-70.</reference_text>
        <pubmed_id>2577144</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>de Mey C, Breithaupt K, Schloos J, Neugebauer G, Palm D, Belz GG: Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther. 1994 Mar;55(3):329-37.</reference_text>
        <pubmed_id>7908256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Sapena R, Morin D, Zini R, Morin C, Tillement JP: Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62.</reference_text>
        <pubmed_id>8741184</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Burgi S, Baltensperger K, Honegger UE: Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action. J Biol Chem. 2003 Jan 10;278(2):1044-52. Epub 2002 Oct 21.</reference_text>
        <pubmed_id>12393876</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Matsumoto K, Ojima K, Ohta H, Watanabe H: Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav. 1994 Sep;49(1):13-8.</reference_text>
        <pubmed_id>7816863</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Samnick S, Scheuer C, Munks S, El-Gibaly AM, Menger MD, Kirsch CM: Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylprop ylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats. Nucl Med Biol. 2004 May;31(4):511-22.</reference_text>
        <pubmed_id>15093822</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Mudunkotuwa NT, Horton RW: Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour. Br J Pharmacol. 1996 Apr;117(7):1481-6.</reference_text>
        <pubmed_id>8730743</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acebutolol</name>
        <accession>HMDB15324</accession>
      </metabolite>
      <reference>
        <reference_text>van den Meiracker AH, Man in 't Veld AJ, Fischberg DJ, Molinoff PB, van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA: Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density. J Cardiovasc Pharmacol. 1988 Apr;11(4):413-23.</reference_text>
        <pubmed_id>2453744</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acebutolol</name>
        <accession>HMDB15324</accession>
      </metabolite>
      <reference>
        <reference_text>Abrahamsson T: Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70. Eur J Pharmacol. 1989 May 2;164(1):121-8.</reference_text>
        <pubmed_id>2568935</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acebutolol</name>
        <accession>HMDB15324</accession>
      </metabolite>
      <reference>
        <reference_text>Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.</reference_text>
        <pubmed_id>16268148</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acebutolol</name>
        <accession>HMDB15324</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nadolol</name>
        <accession>HMDB15334</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nadolol</name>
        <accession>HMDB15334</accession>
      </metabolite>
      <reference>
        <reference_text>Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8.</reference_text>
        <pubmed_id>7981009</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nadolol</name>
        <accession>HMDB15334</accession>
      </metabolite>
      <reference>
        <reference_text>Koshiji M, Ito H, Minatoguchi S, Watanabe H, Imai Y, Kakami M, Hirakawa S: A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing. Clin Exp Pharmacol Physiol. 1992 Jul;19(7):481-8.</reference_text>
        <pubmed_id>1354084</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nadolol</name>
        <accession>HMDB15334</accession>
      </metabolite>
      <reference>
        <reference_text>Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium.  Br J Pharmacol. 1999 Jun;127(4):895-902.</reference_text>
        <pubmed_id>10433496</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nadolol</name>
        <accession>HMDB15334</accession>
      </metabolite>
      <reference>
        <reference_text>Varma DR: Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists. Can J Physiol Pharmacol. 1999 Dec;77(12):943-9.</reference_text>
        <pubmed_id>10606440</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nadolol</name>
        <accession>HMDB15334</accession>
      </metabolite>
      <reference>
        <reference_text>Wheeldon NM, McDevitt DG, Lipworth BJ: Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.  Br J Clin Pharmacol. 1994 Apr;37(4):363-9.</reference_text>
        <pubmed_id>7912539</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levobunolol</name>
        <accession>HMDB15341</accession>
      </metabolite>
      <reference>
        <reference_text>Lesar TS: Comparison of ophthalmic beta-blocking agents.  Clin Pharm. 1987 Jun;6(6):451-63.</reference_text>
        <pubmed_id>2891463</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levobunolol</name>
        <accession>HMDB15341</accession>
      </metabolite>
      <reference>
        <reference_text>Harris A, Malinovsky V, Martin B: Correlates of acute exercise-induced ocular hypotension.  Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3852-7.</reference_text>
        <pubmed_id>7928182</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levobunolol</name>
        <accession>HMDB15341</accession>
      </metabolite>
      <reference>
        <reference_text>Chidlow G, Melena J, Osborne NN: Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol. 2000 Jun;130(4):759-66.</reference_text>
        <pubmed_id>10864881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levobunolol</name>
        <accession>HMDB15341</accession>
      </metabolite>
      <reference>
        <reference_text>Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL: Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J Ocul Pharmacol Ther. 2001 Aug;17(4):305-17.</reference_text>
        <pubmed_id>11572462</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levobunolol</name>
        <accession>HMDB15341</accession>
      </metabolite>
      <reference>
        <reference_text>Brooks AM, Gillies WE: Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.  Drugs Aging. 1992 May-Jun;2(3):208-21.</reference_text>
        <pubmed_id>1351412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levobunolol</name>
        <accession>HMDB15341</accession>
      </metabolite>
      <reference>
        <reference_text>Gonzalez JP, Clissold SP: Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987 Dec;34(6):648-61.</reference_text>
        <pubmed_id>2892662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metipranolol</name>
        <accession>HMDB15345</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metipranolol</name>
        <accession>HMDB15345</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metipranolol</name>
        <accession>HMDB15345</accession>
      </metabolite>
      <reference>
        <reference_text>Drimal J, Knezl V, Magna D, Strizova K: External transport of beta-adrenergic binding sites in ischemic myocardium.  Gen Physiol Biophys. 1987 Dec;6(6):583-91.</reference_text>
        <pubmed_id>2895037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metipranolol</name>
        <accession>HMDB15345</accession>
      </metabolite>
      <reference>
        <reference_text>Arai K, Wood JP, Osborne NN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003 Sep 26;985(2):176-86.</reference_text>
        <pubmed_id>12967722</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metipranolol</name>
        <accession>HMDB15345</accession>
      </metabolite>
      <reference>
        <reference_text>Bilcikova L, Bauer V, Kolena J: The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101.</reference_text>
        <pubmed_id>2885244</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenoterol</name>
        <accession>HMDB15405</accession>
      </metabolite>
      <reference>
        <reference_text>Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17.</reference_text>
        <pubmed_id>14730417</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pirbuterol</name>
        <accession>HMDB15407</accession>
      </metabolite>
      <reference>
        <reference_text>van Zwieten PA: Receptor-mediated inotropic drugs.  Eur Heart J. 1988 Jun;9 Suppl H:85-90.</reference_text>
        <pubmed_id>2901958</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pirbuterol</name>
        <accession>HMDB15407</accession>
      </metabolite>
      <reference>
        <reference_text>Kenakin TP, Beek D: Relative efficacy of prenalterol and pirbuterol for beta-1 adrenoceptors: measurement of agonist affinity by alteration of receptor number. J Pharmacol Exp Ther. 1984 May;229(2):340-5.</reference_text>
        <pubmed_id>6143816</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bevantolol</name>
        <accession>HMDB15409</accession>
      </metabolite>
      <reference>
        <reference_text>Hino T, Sakai K, Ichihara K, Abiko Y: Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs. Pharmacol Toxicol. 1989 Apr;64(4):324-8.</reference_text>
        <pubmed_id>2568629</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bevantolol</name>
        <accession>HMDB15409</accession>
      </metabolite>
      <reference>
        <reference_text>Dukes ID, Vaughan Williams EM: Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80.</reference_text>
        <pubmed_id>2858236</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bevantolol</name>
        <accession>HMDB15409</accession>
      </metabolite>
      <reference>
        <reference_text>Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10.</reference_text>
        <pubmed_id>6148733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bevantolol</name>
        <accession>HMDB15409</accession>
      </metabolite>
      <reference>
        <reference_text>Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.  J Clin Pharmacol. 1987 Jul;27(7):450-60.</reference_text>
        <pubmed_id>2888789</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bevantolol</name>
        <accession>HMDB15409</accession>
      </metabolite>
      <reference>
        <reference_text>Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16.</reference_text>
        <pubmed_id>17628611</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Practolol</name>
        <accession>HMDB15411</accession>
      </metabolite>
      <reference>
        <reference_text>Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64.</reference_text>
        <pubmed_id>2871880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Practolol</name>
        <accession>HMDB15411</accession>
      </metabolite>
      <reference>
        <reference_text>Keyrilainen O, Uusitalo A: A comparative study of three beta 1-adrenoreceptor blocking drugs with different degree of intrinsic stimulating activity (metoprolol, practolol and H 87/07) in patients with angina pectoris. Ann Clin Res. 1978 Aug;10(4):185-90.</reference_text>
        <pubmed_id>30388</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Practolol</name>
        <accession>HMDB15411</accession>
      </metabolite>
      <reference>
        <reference_text>Saarnivaara L, Lindgren L, Hynynen M: Effects of practolol and metoprolol on QT interval, heart rate and arterial pressure during induction of anaesthesia. Acta Anaesthesiol Scand. 1984 Dec;28(6):644-8.</reference_text>
        <pubmed_id>6524278</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Practolol</name>
        <accession>HMDB15411</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Penbutolol</name>
        <accession>HMDB15447</accession>
      </metabolite>
      <reference>
        <reference_text>Venter CP, Joubert PH: Ethnic differences in beta-1-adrenoceptor sensitivity.  S Afr Med J. 1982 Nov 27;62(23):849-50.</reference_text>
        <pubmed_id>6755764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Penbutolol</name>
        <accession>HMDB15447</accession>
      </metabolite>
      <reference>
        <reference_text>Sanchez C: Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats. Behav Pharmacol. 1993 Jun;4(3):269-277.</reference_text>
        <pubmed_id>11224195</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Penbutolol</name>
        <accession>HMDB15447</accession>
      </metabolite>
      <reference>
        <reference_text>Doze P, Elsinga PH, Maas B, Van Waarde A, Wegman T, Vaalburg W: Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET. Neurochem Int. 2002 Feb;40(2):145-55.</reference_text>
        <pubmed_id>11738481</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clenbuterol</name>
        <accession>HMDB15477</accession>
      </metabolite>
      <reference>
        <reference_text>Baker JG: The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010 Jul;160(5):1048-61.</reference_text>
        <pubmed_id>20590599</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxprenolol</name>
        <accession>HMDB15520</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxprenolol</name>
        <accession>HMDB15520</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxprenolol</name>
        <accession>HMDB15520</accession>
      </metabolite>
      <reference>
        <reference_text>Campbell CA, Parratt JR, Kane KA, Bullock G: Effects of prolonged administration of oxprenolol on severity of ischaemic arrhythmias, enzyme leakage, infarct size, and intracellular cardiac muscle action potentials. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):369-77.</reference_text>
        <pubmed_id>6202960</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxprenolol</name>
        <accession>HMDB15520</accession>
      </metabolite>
      <reference>
        <reference_text>Lemmer B: [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)]. Herz. 1982 Jun;7(3):168-78.</reference_text>
        <pubmed_id>6124492</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxprenolol</name>
        <accession>HMDB15520</accession>
      </metabolite>
      <reference>
        <reference_text>Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64.</reference_text>
        <pubmed_id>2871880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxprenolol</name>
        <accession>HMDB15520</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nebivolol</name>
        <accession>HMDB15594</accession>
      </metabolite>
      <reference>
        <reference_text>Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics.  Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.</reference_text>
        <pubmed_id>16961165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nebivolol</name>
        <accession>HMDB15594</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nebivolol</name>
        <accession>HMDB15594</accession>
      </metabolite>
      <reference>
        <reference_text>de Boer RA, Voors AA, van Veldhuisen DJ: Nebivolol: third-generation beta-blockade.  Expert Opin Pharmacother. 2007 Jul;8(10):1539-50.</reference_text>
        <pubmed_id>17661735</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Mersmann HJ: Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci. 1998 Jan;76(1):160-72.</reference_text>
        <pubmed_id>9464897</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>El-Armouche A, Eschenhagen T: Beta-adrenergic stimulation and myocardial function in the failing heart.  Heart Fail Rev. 2009 Dec;14(4):225-41.</reference_text>
        <pubmed_id>19110970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Gilsbach R, Hein L: Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. Handb Exp Pharmacol. 2008;(184):261-88.</reference_text>
        <pubmed_id>18064417</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ: Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):496-503. Epub 2003 Nov 8.</reference_text>
        <pubmed_id>14608456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77.</reference_text>
        <pubmed_id>1687398</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Berendsen HH, Broekkamp CL, Van Delft AM: Antagonism of 8-OH-DPAT-induced behaviour in rats.  Eur J Pharmacol. 1990 Oct 2;187(1):97-103.</reference_text>
        <pubmed_id>2148726</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Watkins DJ, Lawrence AJ, Lewis SJ, Jarrott B: Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996 Aug 27;60(1-2):12-6.</reference_text>
        <pubmed_id>8884690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bopindolol</name>
        <accession>HMDB15696</accession>
      </metabolite>
      <reference>
        <reference_text>Brodde OE, Michel MC, Wang XL, Zerkowski HR: Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J Hypertens Suppl. 1988 Dec;6(4):S497-500.</reference_text>
        <pubmed_id>2907348</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bupranolol</name>
        <accession>HMDB15697</accession>
      </metabolite>
      <reference>
        <reference_text>Zelaszczyk D, Kozlowska H, Baranowska U, Baranowska M, Reutelsterz A, Kiec-Kononowicz K, Malinowska B, Schlicker E: Four close bupranolol analogues are antagonists at the low-affinity state of beta1-adrenoceptors. J Physiol Pharmacol. 2009 Mar;60(1):51-60.</reference_text>
        <pubmed_id>19439807</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
